NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 194 filers reported holding NEVRO CORP in Q4 2017. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $506,000 | -99.9% | 13 | -99.8% | 0.00% | -100.0% |
| Q3 2017 | $491,116,000 | +27.9% | 5,404 | +4.8% | 0.04% | +20.6% |
| Q2 2017 | $383,910,000 | +61.5% | 5,158 | +103.3% | 0.03% | +54.5% |
| Q1 2017 | $237,717,000 | +34.4% | 2,537 | +4.2% | 0.02% | 0.0% |
| Q4 2016 | $176,927,000 | -26.5% | 2,435 | -25.4% | 0.02% | -26.7% |
| Q2 2016 | $240,753,000 | – | 3,264 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
| Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
| TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
| ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
| Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
| Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
| PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
| Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |